Target Population Estimation in German Orphan Drug HTA: Trends and Differences in Epidemiological Data Sources

Estimating target populations for orphan drugs is challenging because epidemiological evidence is limited and heterogeneous. We examined data sources used in German health technology assessment (HTA), temporal trends, and differences between oncology and non-oncology procedures. We retrospectively analyzed German orphan drug HTA procedures completed from 2012 to 2025. Public manufacturer dossiers, IQWiG assessments, and Federal Joint Committee resolutions were reviewed, and procedures classified by the primary epidemiological source were used to derive the final statutory health insurance target population estimate. Among 162 procedures, Literature was the most frequent primary source (43.2%), followed by Literature and Registry data (17.3%), Routine data (16.0%), and Registry data (15.4%). Use of Routine data increased from 3.7% in 2012–2015 to 25.0% in 2021–2025. Source distributions differed significantly between oncology and non-oncology procedures (χ2(3) = 36.8, p < 0.001; Cramér’s V = 0.477), with greater use of registry-based sources in oncology. An exact Monte Carlo analysis of the unpooled table confirmed the association (p < 0.0001). Epidemiological evidence sources were heterogeneous, while use of Routine data increased substantially over time. Stronger registries, coding systems, and responsible secondary use of healthcare data may improve future rare disease target population estimates.

Authors

Institutions

Publication Details

Journal
Journal of Market Access & Health Policy
Published
2026-11-16
DOI
https://doi.org/10.3390/jmahp14040069
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Target Population Estimation in German Orphan Drug HTA: Trends and Differences in Epidemiological Data Sources

Bernhard J. Güntert, Matthias Roll
Journal of Market Access & Health Policy
Pharmaceutical Economics and Policy
article

Target Population Estimation in German Orphan Drug HTA: Trends and Differences in Epidemiological Data Sources

Bernhard J. Güntert, Matthias Roll
article en

Abstract

Estimating target populations for orphan drugs is challenging because epidemiological evidence is limited and heterogeneous. We examined data sources used in German health technology assessment (HTA), temporal trends, and differences between oncology and non-oncology procedures. We retrospectively analyzed German orphan drug HTA procedures completed from 2012 to 2025. Public manufacturer dossiers, IQWiG assessments, and Federal Joint Committee resolutions were reviewed, and procedures classified by the primary epidemiological source were used to derive the final statutory health insurance target population estimate. Among 162 procedures, Literature was the most frequent primary source (43.2%), followed by Literature and Registry data (17.3%), Routine data (16.0%), and Registry data (15.4%). Use of Routine data increased from 3.7% in 2012–2015 to 25.0% in 2021–2025. Source distributions differed significantly between oncology and non-oncology procedures (χ2(3) = 36.8, p < 0.001; Cramér’s V = 0.477), with greater use of registry-based sources in oncology. An exact Monte Carlo analysis of the unpooled table confirmed the association (p < 0.0001). Epidemiological evidence sources were heterogeneous, while use of Routine data increased substantially over time. Stronger registries, coding systems, and responsible secondary use of healthcare data may improve future rare disease target population estimates.

Journal of Market Access & Health PolicyVol. 14(4)
Private University in the Principality of Liechtenstein (LI)
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon